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ABSTRACT
Background: The eosinophil is deeply associated with the pathogenesis of bronchial asthma and other aller-
gic diseases. We recently identified a novel eosinophil-specific cell surface molecule, major facilitator super
family domain containing 10 (Mfsd10). A monoclonal antibody (mAb) against Mfsd10 (M2) showed selective
binding and neutralizing activities for eosinophils. However, the relative potency of the blockage of Mfsd10 and
other eosinophil-specific molecules for the treatment of allergic diseases has not been evaluated. Therefore, in
this study, the effects of M2 and an anti-Siglec-F mAb on antigen-immunized and antigen-specific Th2 cell-
transferred murine eosinophilic inflammation models were comparatively investigated.
Methods: Ovalbumin (OVA)-specific Th2 cells were differentiated from naïve CD4+ T cells of DO11.10RAG-
2-- mice in vitro and cytokine producing activity of the Th2 cells was examined. OVA-immunized and Th2 cell-
transferred BALBc mice were treated with M2 or anti-Siglec-F and challenged with OVA. Then the number of
inflammatory cells and the concentration of IL-5 in the bronchoalveolar lavage fluid (BALF) were determined.
Results: Antigen-specific Th2 cells produced large amounts of IL-4, IL-5 and IL-13 but not IL-17A or IFN-γ. Ad-
ministration of M2 significantly suppressed antigen-induced lung eosinophil infiltration both in OVA-immunized
and Th2 cell-transferred mice. The potency as well as selectivity of M2 for down-regulating eosinophils was
quite similar to that of anti-Siglec-F. Both mAbs did not affect antigen-induced IL-5 production in the lungs.
Conclusions: Mfsd10 as well as Siglec-F could be an effective target to treat eosinophil-related disorders in-
cluding bronchial asthma.
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INTRODUCTION
Eosinophilic inflammation is a prominent feature of
allergic diseases including bronchial asthma.1-4 The
growth, maturation and survival of eosinophils are
mediated by Th2 cytokines, such as IL-3, IL-4, IL-5
and GM-CSF.4 Mature eosinophils secret several cy-
tokines, lipid mediators and toxic granule proteins
that induce local inflammation, epithelial fibrosis and
airway remodeling.4 Compared to healthy control,
asthmatic patients showed an increase in the number
of eosinophils in blood, bronchial mucosa and bron-
choalveolar lavage fluid (BALF).1-3 About 10 years
ago, the role of eosinophils in the pathogenesis of
bronchial asthma was controversial, since anti-IL-5
therapy did not effectively improve the symptoms of
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asthmatic patients.5,6 However, recent clinical studies
for targeting eosinophils, including the newly de-
signed anti-IL-5 therapy, have shown that this cell
type is exactly involved in an exacerbation of asth-
matic symptom.7-9
To identify andor neutralize eosinophils, antibod-
ies (Abs) against cell surface molecules selectively
expressed on eosinophils is useful. In addition to the
receptor for IL-5, several eosinophil-specific mole-
cules such as Siglec-F and CCR3 have been re-
ported.10-12 Administration of monoclonal Abs (mAbs)
against Siglec-F, CCR3 and IL-5 receptor α induced a
significant reduction of eosinophils recruited in the
allergic tissues.13-17
Major facilitator super family domain containing 10
(Mfsd10) was originally identified as a yeast TPO1
gene, which belongs to the major facilitator super
family.18 It was suggested that Mfsd10 is a trans-
porter which uptakes organic anions such as in-
domethacin and fluorescein.19 By means of microar-
ray analysis over the mRNA library established from
a series of murine white blood cells, we previously
identified that Mfsd10 was selectively expressed on
eosinophils.20 Flow cytometric analysis revealed that
a mAb against Mfsd10, M2, was reactive with eosino-
phils in the BALF of antigen-immunized and
-challenged mice.20 However, the ability of anti-
Mfsd10 therapy to treat local eosinophilic inflamma-
tion in allergic diseases has not been elucidated.
We have recently established a new eosinophilic in-
flammation model completely dependent on Th2
cells. Upon antigen challenge, massive eosinophil ac-
cumulation in the lungs accompanied by significant
bronchial hyperresponsiveness was observed in mice
transferred with in vitro-differentiated antigen-
specific Th2 cells.21-23 In this model, we have already
confirmed that the blockage of IL-5 as well as CCR3
effectively suppressed the infiltration of eosino-
phils.21,22 Therefore, by employing the Th2 cell trans-
fer model as well as commonly used antigen immuni-
zation model, we here comparatively investigated the
effects of M2 and anti-Siglec-F mAb on antigen-
induced eosinophilic inflammation in the lungs. The
mechanisms of these effects were further explored by
analyzing cytokine levels in the BALF.
METHODS
ANIMALS
Six-week-old female BALBc mice were purchased
from Japan SLC (Shizuoka, Japan). DO11.10RAG-2--
mice were generated and maintained for antigen-
specific Th2 cell preparation as described previ-
ously.23 The experimental protocols were approved
by the Animal Use and Care Committee of Tokyo
Metropolitan Institute of Medical Science.
ANTIBODIES
M2 was established as described previously.20 Rat
IgG Ab and anti-Siglec-F mAb were purchased from
Inter-Cell Technologies (FL, USA) and R & D Sys-
tems (MN, USA), respectively.
IN VITRO POLARIZATION OF TH2 CELLS
Ovalbumin (OVA)-specific naïve CD4+ T cells were
isolated from splenocytes of DO11.10RAG-2-- mice
by positive selection using CD4 microbeads and mag-
netic cell sorting system (Miltenyi, Bergisch Glad-
bach, Germany). Cells were cultured with X-ray-
irradiated splenocytes in DMEM-F12HAM medium
(Sigma-Aldrich, MO, USA) supplemented with 10%
fetal bovine serum. At the start of culture, 0.3 μM syn-
thetic OVA323-339 peptide, 10 Uml recombinant IL-
2 (Shionogi, Osaka, Japan), 10 Uml recombinant IL-
4 (PeproTech, NJ, USA) and 10 μgml anti-IFN-γ
mAb (R4-6A2, eBioscience, CA, USA) were added as
described previously.23 Seven days after the stimula-
tion, cells were harvested and used for the adoptive
transfer. To determine the integrity of polarization,
the resulting Th2 cells (1 × 105) were incubated with
X-ray-irradiated splenocytes (2 × 105) with or without
0.3 μM OVA peptide for 24 h. The concentrations of
cytokines in the culture supernatants were deter-
mined by a bead-based multiplex immunoassay sys-
tem using Bio-plex Pro Mouse Cytokine Assay (Bio-
Rad Laboratories, CA. USA), according to the manu-
facturer’s instructions. Detection limits of IL-1β, IL-4,
IL-5, IL-13, IL-17A and IFN-γ were 375, 25, 20, 55, 15
and 30 pgml, respectively.
AIRWAY EOSINOPHILIC INFLAMMATION MOD-
ELS
In the antigen immunization model, mice were sensi-
tized by intraperitoneal injection of 20 μg OVA
(Sigma-Aldrich) emulsified with 2.25 mg alum
(Thermo Fisher Scientific, MA, USA) on days 0, 7, 14
and 21 of the experiment. On days 35-37, mice were
challenged 3 times by daily intratracheal administra-
tion of 375 μg OVA dissolved in 25 μl saline or saline
alone. Twenty-four hours before the first challenge
and 5 h after the last challenge, 20 mgkg M2, 4 mg
kg anti-Siglec-F mAb or control rat IgG was adminis-
trated intravenously (Fig. 1A). In Th2 cell transfer
model, polarized Th2 cells (2 × 107) were intrave-
nously injected in each BALBc mouse on day 0, and
then mice were challenged by intratracheal admini-
stration of OVA or saline on day 1. Two hours before
and 24 h and 48 h after the challenge, mice were in-
travenously injected three times with M2, anti-Siglec-
F or control rat IgG (Fig. 1B). In both models, the
most effective dose and timing of Ab administration
were determined by serial preliminary experiments.
BAL was performed 72 h after the last challenge and
inflammatory cells in the BALF were classified by
means of morphological criteria as described previ-
ously.20,23 The concentrations of IL-4, IL-5, IL-13 and
eotaxin in the BALF were determined by ELISA with
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Fig.　1　Timeline of the experimental protocol. Mice were 
sensitized 4 times with OVA plus alum once a week. On 
days 35-37, mice were challenged by intratracheal injection 
with OVA. Ab administration was performed on days 34 and 
37. BAL was performed 72 h after the last challenge (A). Af-
ter the transfer of polarized Th2 cells on day 0, mice were 
challenged with OVA on day 1. Ab was administrated three 
times on days 1, 2 and 3. BAL was performed 72 h after the 
last challenge (B).
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Fig.　2　Cytokine production by Th2 cells in vitro. Polarized 
Th2 cells were stimulated with OVA323-339 peptide or were 
left unstimulated. Twenty-four hours later, the concentrations 
of cytokines in the culture supernatants were measured by 
the bead-based multiplex immunoassay system. Data are 
expressed as mean ± SEM of triplicate cultures. The results 
shown are representative of two separate experiments. N.D., 
not detectable.
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mouse ELISA kits (eBioscience) according to the
manufacture’s protocol. Detection limits of these as-
say systems were 16, 8, 16, 31 pgml, respectively.
STATISTICAL ANALYSIS
The results were presented as arithmetic mean ±
SEM. Statistical analysis was performed by one-way
ANOVA and Dunnett’s multiple comparison test. p <
0.05 was considered to indicate statistical signifi-
cance.
RESULTS
CHARACTERIZATION OF POLARIZED TH2
CELLS IN VITRO
To evaluate the polarization state of in vitro-cultured
antigen-specific CD4+ T cells under Th2 differentia-
tion conditions, cells were stimulated with OVA323-
339 peptide, and then concentrations of various cy-
tokines in the culture supernatants were determined.
As shown in Figure 2, antigen-stimulated Th2 cells
secreted large amounts of IL-4, IL-5 and IL-13, how-
ever these cytokines were not detectable without
stimulation. IL-17A was produced very little only by
stimulated cells. Weak but constitutive IL-1β produc-
tion was observed, whereas IFN-γ was not detectable
with or without antigen stimulation. These findings
suggest that antigen-specific T cells used for adoptive
transfer in this study were appropriately differenti-
ated into Th2 cells.
EFFECTS OF M2 AND ANTI-SIGLEC-F mAB ON
LUNG EOSINOPHIL INFILTRATION
The effects of M2 and an anti-Siglec-F mAb on
antigen-induced lung eosinophil accumulation were
comparatively investigated in antigen-immunized
mice. The number of eosinophils in the BALF was
significantly increased upon OVA challenge (Fig. 3).
Administration of M2 as well as anti-Siglec-F signifi-
cantly suppressed the infiltration of eosinophils. The
accumulation of other inflammatory cells, such as
lymphocytes, neutrophils and monocytesmacro-
phages in the lungs was also observed following anti-
gen challenge, though it was not statistically signifi-
cant. Moreover, these inflammatory cells other than
eosinophils were not affected by administration of M2
or anti-Siglec-F (Fig. 3).
Next, we examined the ability of M2 to down-
regulate Th2 cell-mediated lung eosinophilia. Th2
cell-transferred mice were administrated with each
mAb and were challenged with OVA. Similar to the
case of the antigen immunization model, massive
eosinophil infiltration into the lungs was occurred,
and the eosinophilia was significantly suppressed by
M2 and anti-Siglec-F (Fig. 4). The numbers of lym-
phocytes, neutrophils, monocytesmacrophages and
total cells in the BALF of M2- and anti-Siglec-F-
administrated mice were not significantly different
from those of control rat IgG-administrated mice.
Both in antigen immunization and Th2 cell transfer
models, the potency as well as selectivity of M2 and
anti-Siglec-F for down-regulating antigen-induced
lung eosinophilia was equivalent.
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Fig.　3　Effects of M2 and anti-Siglec-F mAb on antigen-induced eosinophil infi ltration in an-
tigen-immunized mice. Antigen-immunized mice were challenged with OVA or saline. Twen-
ty-four hours before the fi rst challenge and 5 h after the last challenge, each Ab was admin-
istrated intravenously. The number of cells in the BALF was determined 72 h after the last 
challenge. Data are expressed as mean ± SEM of 4-6 mice. *p < 0.05, **p < 0.01 and ***p < 
0.001, compared with OVA/Rat IgG group.
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Fig.　4　Effects of M2 and anti-Siglec-F mAb on antigen-induced eosinophil infi ltration in 
Th2 cell-transferred mice. Th2 cell-transferred mice were challenged with OVA or saline. 
Each Ab was administrated intravenously three times 2 h before, and 24 h and 48 h after the 
antigen challenge. The number of cells in the BALF was determined 72 h after the last chal-
lenge. Data are expressed as mean ± SEM of 4-6 mice. **p < 0.01 and ***p < 0.001, com-
pared with OVA/Rat IgG group.
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Fig.　5　IL-5 production in lungs of Th2 cell-transferred mice. 
Th2 cell transfer, antigen challenge and BAL were performed 
as described in Figure 1. The concentration of IL-5 in the 
BALF was measured by ELISA. Data are expressed as 
mean ± SEM of 4-6 animals. N.D., not detectable.
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EFFECTS OF M2 AND ANTI-SIGLEC-F mAB ON
IL-5 PRODUCTION
To investigate whether the suppression of the eosino-
phil accumulation by M2 or anti-Siglec-F was caused
by the down-regulation of eosinophil active cytokines,
the effects of these mAbs on the production of IL-5 in
the BALF were investigated. An apparent increase in
the level of IL-5 was observed in the BALF of Th2
cell-transferred and OVA-challenged mice (Fig. 5).
However, administration of M2 or anti-Siglec-F did
not affect the production of IL-5. Not only eosinophil-
active chemokines such as eotaxin but also other Th2
cytokines such as IL-4 and IL-13 were not detectable
in these experimental conditions. Therefore, it is
most likely that the inhibition of eosinophil infiltration
by M2 and anti-Siglec-F was due to their direct effects
on eosinophils, rather than to the down-regulation of
eosinophil-active cytokineschemokines.
DISCUSSION
The recruitment of eosinophils into the target organs
is one of the critical pathogenetic mechanisms of al-
lergic diseases. In this study, significant suppression
of antigen-induced lung eosinophil infiltration was
achieved by administration of the mAb, M2, against
a novel eosinophil-specific cell surface molecule,
Mfsd10, in two different allergic inflammation mod-
els. The efficacy of M2 was comparable to that of anti-
Siglec-F mAb and was not due to the inhibition of IL-5
production.
The effect of M2 was highly selective on eosino-
phils. Thus, both in antigen immunization and Th2
transfer models, accumulation of eosinophils but not
lymphocytes, neutrophils or monocytesmacro-
phages in the BALF was significantly affected by M2.
These findings are consistent with our previous ob-
servations that mRNA expression level of Mfsd10 was
much higher in eosinophils than in B cells, T cells,
monocytesmacrophages, neutrophils, basophils and
dendritic cells.20 In addition, we also demonstrated
that more than 97% of M2-positive cells in the BALF
of antigen-immunized and -challenged mice were
CCR3+Siglec-F+ eosinophils.20
The suppression of eosinophil accumulation was
also displayed by anti-Siglec-F mAb. The potency of
this mAb against lung eosinophil accumulation both
in antigen immunization and Th2 transfer models was
similar to that of M2. These finding are consistent
with a previous report showing that intact as well as
F(ab’)2 fragments of anti-Siglec-F mAb similarly sup-
pressed antigen-induced lung eosinophilia in mice.13
Zimmermann et al. also demonstrated that admini-
stration of anti-Siglec-F Ab also decreased the num-
ber of peripheral blood eosinophils.14 However, the
down-regulation of eosinophils but not neutrophils by
anti-Siglec-F in this study was not supported by our
previous data that mRNA of Siglec-F was equivalently
expressed in eosinophils and neutrophils.20 Zhang et
al. also reported that weak expression of Siglec-F was
observed on mouse neutrophils.24 On the other hand,
the suppressive effect of anti-Siglec-F on neutrophil
infiltration was not demonstrated by Song et al..13
The reason for the contradiction is unclear, although
the allergic inflammation models employed in this
study especially featured eosinophils. Therefore, in
order to elucidate the exact role of Siglec-F on neu-
trophils, the effect of anti-Siglec-F is required to be in-
vestigated in some neutrophil-rich inflammation
model. Most importantly, it is clearly suggested that
Mfsd10 is a critical target for the selective down-
regulation of eosinophil accumulation in allergic dis-
eases.
The eosinophil is crucially involved in an important
pathological feature of bronchial asthma, airway re-
modeling. It was reported that antigen-induced peri-
bronchial fibrosis was diminished by administration
of anti-Siglec-F due to reduction of eosinophil-derived
TGF-β1.13 Anti-CCR3 mAb was also reported to re-
duce mucus accumulation or subepithelial basement
membrane thickness, according to the suppression of
eosinophil infiltration.15 These previous findings sug-
gest the possible management of airway remodeling
by anti-Mfsd10 Ab. Further investigations are re-
quired to elucidate the effect of M2 on antigen-
induced airway remodeling models.
IL-5 is mainly produced by activated Th2 as well as
mast cells and eosinophils,25,26 and regulates the dif-
ferentiation, maturation, migration, development, sur-
vival, trafficking and effector function of eosinophils.4
In this regard, it seems that inhibition of the eosino-
phil accumulation by M2 and anti-Siglec-F was contra-
dictory to their ineffectiveness on IL-5 production.
However, in a series of our previous investigation em-
ploying Th2 cell-transferred mice, the cellular source
of IL-5 was mostly designated as antigen-specific T
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cells already distributed in the lungs before the chal-
lenge.21,27 Consequently, M2 as well as Siglec-F could
down-regulate the eosinophilia without affecting the
BALF IL-5 level in this study. Eosinophils may con-
tribute as sources of IL-5 in more chronic inflamma-
tory sites in asthma.
It was reported that Abs against Siglec-8, a human
paralog of Siglec-F, induced caspase- andor reactive
oxygen species-dependent apoptosis of eosino-
phils.28-30 Although mechanisms of M2 to suppress
infiltration of eosinophils are needed to be elucidated,
Ushijima et al. reported that Mfsd10 is a membrane
transporter which uptake of organic anions.19 There-
fore, delineating the role of this transporter in eosino-
phil functions is also required.
Conclusively, M2 and anti-Siglec-F selectively sup-
pressed antigen-induced lung eosinophilic infiltration.
Mfsd10 is a potential target to treat eosinophil-related
disorders including bronchial asthma.
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